[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 184.73.122.162. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1993

Low Dose Recombinant Interferon Alfa Treatment for Classic Kaposi's Sarcoma

Author Affiliations

From the Departments of Dermatology (Drs Tur and Brenner) and Hematology (Dr Michalevicz), Tel Aviv Sourasky Medical Center, Tel Aviv University, Sackler School of Medicine, Israel.

Arch Dermatol. 1993;129(10):1297-1300. doi:10.1001/archderm.1993.01680310067011
Abstract

Background:  High doses of interferon alfa are used to treat Kaposi's sarcoma in patients with immunodeficiency, whereas low doses are generally ineffective. Following low-dose recombinant interferon alfa treatment for lymphoma, two patients showed a regression of their hematologic malignancy-associated Kaposi's sarcoma. This observation prompted us also to try lowdose interferon alfa treatment in uncomplicated classic Kaposi's sarcoma, and two additional patients were thus treated on an outpatient basis.

Observations:  Initial response was noted after 3 to 13 weeks of treatment. Remission was achieved after 4 to 6 months of low-dose interferon alfa treatment and its duration was 8 to 14 months. Recurrences were treated again and additional remissions were obtained after only 5 to 8 weeks of treatment.

Conclusion:  Low-dose interferon alfa treatment may represent an effective therapeutic modality for the treatment of patients with both lymphoma-associated and uncomplicated classic Kaposi's sarcoma.(Arch Dermatol. 1993;129:1297-1300)

×